Nicox Provides Full Year 2025 Financial Results and Corporate Update
April 30, 2026 01:30 ET | Source: NICOX SA Press Release Nicox…
CORRECTION — Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs
Company Planning Multi-Pronged Approach for QRX009 Including Several Investigator Led Clinical Studies…
Oncotelic Therapeutics Provides Corporate Update on Partnership Strategy
AGOURA HILLS, Calif., April 24, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc.…
Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update
– Released positive topline data from Phase 1 study of IV rademikibart…
Vivoryon Therapeutics N.V. Provides Update on Growing Body of Evidence Validating Glutaminyl Cyclases as Promising Targets in DKD at World Congress of Nephrology
Vivoryon Therapeutics N.V. Provides Update on Growing Body of Evidence Validating Glutaminyl…
Ascentage Pharma Reports Full Year 2025 Unaudited Financial Results and Provides Business Updates
Product sales and commercial rights revenues in 2025 increased 90% year-over-year to…
Renewal Fuels, Inc. (OTC: RNWF), Operating as American Fusion, Provides Regulatory and Legal Update
SOUTHLAKE, Texas, March 16, 2026 (GLOBE NEWSWIRE) -- Renewal Fuels, Inc. (OTC:…
CORRECTING & REPLACING — MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism
Following End-of-Phase 2 meeting, MBX remains on track to initiate Phase 3…
CGTN: How China’s development path provides a model for global growth
BEIJING, March 4, 2026 /PRNewswire/ -- As China's annual Two Sessions gets…
TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Presented positive updated data from the ALLOHA™ Phase 1 heme trial at…
